Skip to main content

Practice Management

Practice Management
Lessons from the Leucovorin Shortages Between 2009 and 2012 in a Medicare Advantage Population: Where Do We Go from Here?
Mary S. Hayes, PharmD, S. Lane Slabaugh, PharmD, MBA, Melea A. Ward, PharmD, MS, Yihua Xu, PhD
Stakeholder Perspective
Drug Shortages Are Costly to Patients and to Payers
by Joseph P. Fuhr, Jr, PhD
Read More
Practice Management
Offering Lung Cancer Screening to High-Risk Medicare Beneficiaries Saves Lives and Is Cost-Effective: An Actuarial Analysis
Ellynne Dec, ASA, MAAA, Claudia I. Henschke, PhD, MD, David F. Yankelevitz, MD, Rowena Yip, MPH, Bruce S. Pyenson, FSA, MAAA
Stakeholder Perspective
Cost-Effectiveness and the Medicare Budget
by Joseph R. Antos, PhD
Read More
Practice Management
The Health and Economic Effects of Counterfeit Drugs
Erwin A. Blackstone, PhD, Joseph P. Fuhr, Jr, PhD, Steve Pociask, MA
Stakeholder Perspective
The Hidden Market of Counterfeit Drugs a Concern for All Stakeholders
by James T. Kenney, RPh, MBA
Read More
Practice Management
The Economic Burden of Ischemic Stroke and Major Hemorrhage in Medicare Beneficiaries with Nonvalvular Atrial Fibrillation: A Retrospective Claims Analysis
Kathryn Fitch, RN, MEd, Jonah Broulette, ASA, MAAA, Winghan Jacqueline Kwong, PharmD, PhD
Stakeholder Perspective
The Clinical Toll of Nonvalvular Atrial Fibrillation Poses Significant Economic Burden
by Raymond L. Singer, MD, MMM, CPE
Read More
Practice Management
The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy- Induced Nausea and Vomiting: Systematic Review of the Literature
Michael S. Broder, MD, MSHS, Claudio Faria, PharmD, MPH, Annette Powers, PharmD, MBA, Jehangeer Sunderji, MD, Dasha Cherepanov, PhD
Stakeholder Perspective
The Value of Pharmaceuticals in the Prevention and Treatment of CINV
by Atheer A. Kaddis, PharmD
Read More
Practice Management
Current Challenges in Health Economic Modeling of Cancer Therapies: A Research Inquiry
Jeffrey D. Miller, MS, Kathleen A. Foley, PhD, Mason W. Russell, MAPE
Stakeholder Perspective
Disruptive Innovation, Uncertain Value, and Economic Modeling in Oncology
by Michael F. Murphy, MD, PhD
Read More
Practice Management
Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend
Christopher M. Blanchette, PhD, MBA, Nicholas J. Gross, MD, PhD, Pablo Altman, MD, MBA, F. Randy Vogenberg, PhD, FASHP
Stakeholder Perspective
Chronic Obstructive Pulmonary Disease Remains a Growing Population Health Concern
Read More
Practice Management
Resource Utilization and Cost in a Commercially Insured Population with Schizophrenia
Kathryn Fitch, RN, MEd, Kosuke Iwasaki, FIAJ, MAAA, Kathleen F. Villa, MS
Stakeholder Perspective
Schizophrenia: “The Forgotten Illness”?
by Atheer A. Kaddis, PharmD
Read More
Practice Management
Insurance Companies’ Perspectives on the Orphan Drug Pipeline
Robert Handfield, PhD, Josh Feldstein, BA
Stakeholder Perspective
Breakthrough Therapy, or Breakthrough Pricing?
by Atheer A. Kaddis, PharmD
Read More
Practice Management
“Project IMPACT: Diabetes” Care Model Improves Health Outcomes in Underserved Populations in 25 Communities with a High Incidence of Diabetes
Benjamin M. Bluml, RPh
Read More
Page 16 of 32
Results 151 - 160 of 318